Refrigerated Stem Cells Survive 12 Times Longer with ProtoKinetix’s AAGP™
News Jun 08, 2007
As a follow up to ProtoKinetix Inc.’s May 23, 2007 press release related to cryopreserved (or frozen) cells treated with AAGP™, in collaboration with the University of Helsinki, Finland, ProtoKinetix has recently finished a set of trials designed to determine whether AAGP™ treated cells could survive after preservation in refrigeration (4°C).
Commenting on the results, ProtoKinetix’s Director of Scientific Affairs, Dr. John Todd, stated, “After 3 days of preservation in refrigeration, untreated stem cells have a very high mortality rate. In the most recent experiments with the University of Helsinki, Finland, it was determined that AAGP™ can significantly reduce this cell death rate. AAGP™ demonstrated an impressive and repetitive 8 to 12 times increase in cell viability and survivability.”
Dr. Todd added, “These results are extremely important and encouraging for isolating the limited stem cell populations found in certain organs and tissues, such as umbilical cord blood and bone marrow. The implications for the treatment of certain types of cancers, such as leukemia and other conditions requiring bone marrow transplant are enormous.”
High blood pressure, or hypertension, is suggested to be one of the leading risk factors for heart disease. The process in which high blood pressure causes heart disease is not completely understood. Now, researchers have found that high blood pressure caused by specific signalling from the brain promotes heart disease by altering stem cells with the bone marrow.READ MORE